Leslie Muenzler
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 477 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,715, 3.1 times the $1,194 reported in 2021. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 477 payments — averaging $25.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Sanofi$1K
- Pfizer$813
- Novartis$493
- plus $5K from 34 others
What the payments were for
- Food & beverage$11,88696%
- Education$4804%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 62 | $2,066 |
| GSK | 92 | $1,450 |
| Regeneron Healthcare Solutions, Inc. | 49 | $1,344 |
| Sanofi | 36 | $1,276 |
| Pfizer | 49 | $813 |
| Novartis | 23 | $493 |
| Dexcom, Inc. | 6 | $487 |
| CSL Behring | 18 | $446 |
| Amgen | 17 | $400 |
| Blueprint Medicines Corporation | 14 | $335 |
| Sanofi-aventis U.S. LLC | 5 | $310 |
| AbbVie | 4 | $294 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $288 |
| Lilly USA, LLC | 5 | $270 |
| Kaleo, Inc. | 15 | $211 |
| Novo Nordisk | 2 | $189 |
| Pharming Healthcare, Inc. | 7 | $166 |
| Mylan Specialty L.p. | 8 | $156 |
| Phathom Pharmaceuticals, Inc. | 10 | $140 |
| Bayer | 2 | $118 |
| Kowa Pharmaceuticals America, Inc. | 1 | $116 |
| Grifols USA, LLC | 5 | $114 |
| Alk-abello, Inc | 5 | $90 |
| Idorsia Pharmaceuticals US Inc | 1 | $89 |
| Mirum Pharmaceuticals, Inc. | 1 | $87 |
| Genentech USA, Inc. | 4 | $73 |
| Octapharma USA, Inc. | 2 | $71 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $58 |
| Viatris Specialty LLC | 2 | $56 |
| Incyte Corporation | 2 | $47 |
| Aimmune Therapeutics, Inc. | 2 | $45 |
| LEO Pharma Inc. | 2 | $45 |
| Hospira, Inc. | 2 | $40 |
| Exact Sciences | 1 | $38 |
| Ionis Pharmaceuticals, Inc. | 1 | $36 |
| Regeneron | 1 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Merck | 1 | $19 |
| Phadia US Inc. | 1 | $14 |
| USWM, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,367 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 47 | $187,541 |
| Fasenra PenBenralizumab | 11 | $72,497 |
| TezspireTezepelumab-Ekko | 16 | $70,237 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $63,889 |
| XolairOmalizumab | 15 | $43,274 |
| NucalaMepolizumab | 12 | $42,019 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $22,525 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $6,088 |
| Montelukast Sodium | 253 | $3,922 |
| Epinephrine | 16 | $3,583 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 63 | $1,597 |
| Azelastine Hcl | 67 | $1,539 |
| Fluticasone Propionate | 85 | $1,433 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 11 | $1,256 |
| Ipratropium Bromide | 29 | $1,124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala | $1,450 | $105,90992 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $2,066 | $98,85072 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Waco
- Jena MannWaco$51K
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.